การวิเคราะห์ผลิตภัณฑ์แบบไม่บังคับ
เมื่อคุณอนุญาต เราจะใช้การวิเคราะห์แบบจำกัดที่คำนึงถึงความเป็นส่วนตัวเพื่อดูว่าเส้นทางการวิจัยใดได้ผล เราไม่ใช้ตัวติดตามโฆษณาหรือการบันทึกเซสชัน คุณเปลี่ยนตัวเลือกนี้ได้ในการตั้งค่า อ่าน นโยบายความเป็นส่วนตัว.
The largest upside opportunity lies in faster-than-projected global GLP-1 adoption and ex-US geographic expansion starting in FY2027.
Top customer revenue growth falls below 2.5% annually or orders decline by more than 15% year-over-year.
We rate West Pharmaceutical Services Sell with a Fair value of $191.60 per share, compared to the October 8, 2026 price of $359.51. Although West maintains an exceptional competitive position in high-value injectable packaging, the current market valuation leaves no margin of safety for operational execution risks or customer concentration shocks.2
Our rating on West Pharmaceutical Services is Sell. For an ordinary investor, this recommendation means capital is at elevated risk at prevailing prices, and existing shareholders should look to trim or exit holdings to protect capital. The stock price reflects market expectations that far outpace the underlying economic earning power of the business, creating substantial downside risk if volume growth moderates.
The stock traded at $359.51 on October 8, 2026. This price stands 87.6% above our Fair value of $191.60 per share, which implies a negative 46.7% return. Even when evaluated against our Potential value of $247.73 per share—representing an optimistic scenario of rapid cleanroom commercialization and sustained high-teens biologics volume growth—the stock trades at a 45.1% premium, indicating that favorable operating results are already more than fully priced in.2
The primary risk that would accelerate downside is customer concentration and client order volatility. West depends on a single pharmaceutical customer for 15.8% of consolidated net sales, totaling $485.9 million across both business segments in FY2025. If this anchor customer slows order rates, experiences end-market commercial setbacks, or qualifies secondary suppliers, manufacturing throughput would stall, reducing revenue growth by 5 percentage points and prompting steep valuation multiple compression.6
The strongest driver supporting business value is the profitable mix shift into proprietary high-value products embedded in regulatory drug filings. Biologics customers contributed 40.0% of consolidated sales in FY2025, and Proprietary Products delivered 16% organic growth in the second quarter of 2026 led by strong demand for GLP-1 and non-GLP-1 elastomer solutions. Because components like NovaPure and FluroTec carry premium selling prices and cannot be substituted without extensive regulatory review, high-margin sales expand operating profit and generate cash, though this expansion remains bounded well below the October 8, 2026 market price.36
Proprietary high-value products such as NovaPure and FluroTec command premium pricing and expanding volume share across rapidly expanding biologics and GLP-1 drug classes, driving segment organic growth of 16% in Q2 2026.3
Capital expenditures declined from peak levels of $377.0 million in FY2024 to $285.9 million in FY2025, allowing cash conversion to accelerate as commercial lines in Grand Rapids and Dublin reach target throughput.35
Elastomer closures embedded into approved drug master files require multi-year stability re-validation for customers to switch suppliers, insulating incumbent volumes and sustaining superior returns on invested capital.13
Sell: West Pharmaceutical Services trades at an 87.6% premium to our Fair value of $191.60 per share, pricing in aggressive growth expectations that leave investors vulnerable to multiple contraction and volume deceleration.2
West Pharmaceutical Services Inc. designs and manufactures specialized packaging and delivery systems for injectable drugs and healthcare products. The company provides primary packaging containment, including proprietary elastomer stoppers, syringe plungers, vial seals, and advanced drug administration systems such as FluroTec and NovaPure components. These engineered solutions protect the efficacy, purity, and stability of sensitive parenteral therapies from fill-finish manufacturing through patient delivery.
The company operates across two reportable segments: Proprietary Products and Contract-Manufactured Products. Proprietary Products accounts for the vast majority of business activity, generating $2,492.1 million in revenue (81.1% of net sales) and $657.2 million in operating profit in FY2025. Contract-Manufactured Products provides custom manufacturing and assembly services for diagnostic and medical devices, generating $582.0 million in revenue (18.9% of net sales) and $63.4 million in operating profit in FY2025.
West serves a diverse global customer base across the life sciences industry, with FY2025 net sales distributed among Biologics accounts (40%), commercial Pharmaceutical clients (24%), Contract Manufacturing partners (19%), and Generics manufacturers (17%). Geographically, the United States represents the largest market with $1,329.6 million in revenue, complemented by substantial European operations across Germany ($380.3 million), Ireland ($333.3 million), France ($226.6 million), and other European markets ($451.0 million).
Under an integrated downside stress test, West faces concurrent operational and concentration shocks. If the primary biopharma customer (representing 15.8% of consolidated net sales or $485.9M in FY2025) initiates dual-sourcing or experiences commercial softness, consolidated revenue growth contracts by 5 percentage points toward 2.5%. Simultaneously, if Dublin cleanroom qualification encounters extended validation delays and synthetic elastomer/commodity oil inflation cannot be fully recovered, operating margins compress toward 17.50% (against 19.03% in FY2025). In this stressed environment, the market's elevated forward P/E of 37.45x de-rates aggressively toward healthcare supplier peer medians (peer median forward P/E 14.16x), driving intrinsic fair value toward the downside range low of $157.85.
In the downside scenario, customer concentration shocks, potential dual-sourcing by the anchor biopharma client, and qualification delays at the Dublin facility compress operating margins and trigger a multiple de-rating toward healthcare supplier peer medians.
West's top customer represents 15.8% of consolidated sales ($485.9M) across both Proprietary and Contract Manufacturing segments. If this customer diversifies supply, experiences competitive displacement, or delays fill-finish runs, consolidated revenue growth contracts by 5 percentage points over the next 5 years, impacting intrinsic fair value by -24.5%.6
ห้าพัฒนาการที่อาจทำให้กรณีการลงทุนของเราอ่อนแอลง
Signals client dual-sourcing, patent expiration, or underlying molecule volume contraction, invalidating customer stability assumptions and reducing consolidated sales by $48M+.
ปัจจุบัน:15.8% of consolidated net sales ($485.9M) in FY2025 across Proprietary and Contract Manufacturing segments
แจ้งเตือนหากRevenue decline of 15% or more YoY from the primary anchor client
West Pharmaceutical Services commands an entrenched wide economic moat in injectable pharmaceutical packaging and delivery systems. The foundation of this advantage lies in proprietary elastomer chemistry and specialized barrier coatings (FluroTec and NovaPure) designed to eliminate chemical interaction, extractables, and particle contamination in sensitive large-molecule therapeutics. Biologics customers accounted for 40.0% of consolidated revenue in FY2025, anchoring high-teens volume growth across high-value product (HVP) lines and supporting 16% organic growth in Proprietary Products in Q2 2026.
The primary structural mechanism preserving West's profitability is high regulatory switching barriers. In injectable therapeutics, containment components are integral to the drug's formulation and are embedded directly into drug master files (DMFs) submitted to global regulatory agencies. Replacing a West stopper or plunger requires biopharmaceutical innovators to execute comprehensive stability testing, biocompatibility assays, and clinical batch verifications, followed by supplemental regulatory approvals taking 3 to 5 years. For an approved commercial therapy, the financial and regulatory risks of switching suppliers vastly exceed any potential component cost savings.
Furthermore, West benefits from efficient scale and specialized manufacturing infrastructure. Over recent fiscal years, West deployed substantial capital ($377.0M in FY2024 and $285.9M in FY2025) to expand high-value containment and drug handling lines at Grand Rapids and Dublin. This installed base allows West to serve global demand for GLP-1 and biologic containment at unit costs and quality yields that potential competitors cannot replicate without massive, uncontracted capital commitments.
These structural advantages translate into superior financial outcomes, evidenced by Proprietary Products segment operating profit of $657.2M on $2,492.1M revenue (26.37% segment margin) in FY2025. While customer concentration exists—with a single client representing 15.8% of consolidated net sales ($485.9M) —the multi-year regulatory lock-in insulates West from customer defection, sustaining returns on invested capital well above capital costs.
West generates significant economic profits, with return on invested capital of ~16.2% to 18.01% consistently exceeding its weighted average cost of capital of 9.57% by over 660 to 840 basis points. In FY2025, operating profit of $584.9M on $3,074.1M revenue and free cash flow of $468.9M confirm robust economic rent extraction, even after absorbing peak multi-year capex expansions.145
Each lens answers a different valuation question. Only included lenses set Fair value; floors and diagnostics provide context.
The highlighted cell is Fair value when every assumption sits at its base level ($191.60). Each row and column shows what Fair value becomes when one assumption moves.
Free cash flow to the firm stays positive in the first projected year at $411.5M after modeled reinvestment of $144.6M, with terminal value at 77.4% of enterprise value. A sudden drop in free cash flow is not projected unless capital spending relative to revenue, reinvestment, or gross margin resets materially.
The base case projects intrinsic Fair value at $191.60 (representing an implied return of -46.7% from $359.51 (as of 2026-10-08)). Under a 65.0% probability weighting, the target is $191.60, delivering an expected return of -46.7%. This reflects steady biologics mix shift, commercial ramp-up at Grand Rapids and Dublin, and gradual margin normalization toward terminal expectations.
A significant operational outperformance confirms faster-than-modeled mix enrichment and operational leverage, narrowing the valuation gap sufficiently to warrant adjusting the rating band from Sell to Reduce, though market price remains well above Fair value.
Results meeting guidance confirm the steady compounding thesis but leave the extreme valuation disconnect unresolved, as market pricing continues to embed expectations far exceeding fundamental cash flow generation.
An operational or margin shortfall would puncture elevated market growth expectations, accelerating multiple contraction toward peer medians and confirming downside risks outlined in the stress test.
Earnings quality is robust, characterized by strong operating cash generation that comfortably exceeds reported GAAP net income. Free cash flow conversion is supported by working capital discipline and disciplined capital expenditures, while the absence of aggressive revenue recognition or capitalized development costs underscores clean underlying accounting. Operating margins in the core proprietary segment are supported by genuine pricing power and product mix enrichment rather than one-off accounting credits.
Consensus estimate revisions have exhibited positive momentum following second-quarter earnings, supported by management raising full-year guidance for organic revenue growth and adjusted diluted earnings per share. High-teens volume growth across high-value packaging components for biologics and injectable therapies has anchored upward earnings revisions, though expectations for subsequent fiscal years remain tightly clustered.
Measures core adoption of high-value injectable containment solutions; deceleration would indicate biopharma customer destocking or slowing volume demand.
Operating cash flow expanded to $754.8M in FY2025, delivering free cash flow of $468.9M as capex stepped down from $377.0M in FY2024 to $285.9M in FY2025. In H1 2026, YTD operating cash flow was $213.9M and free cash flow reached $128.0M after $85.9M of capex. Cash conversion from GAAP net income ($493.7M in FY2025) was 95.0% on free cash flow and 152.9% on operating cash flow, reflecting high-quality earnings backed by tangible cash realization.45
West maintains a disciplined, conservative capital allocation framework. With net debt of -$588.5M ( position) and total debt of only $316.5M against a of $25.30B, the balance sheet is exceptionally under-leveraged (debt weight 1.24%). is prioritized toward organic high-return ($285.9M in FY2025), followed by regular share repurchases that offset annual ($23.8M in FY2025) and drive a net reduction of ~0.6% annually. Dividend distributions remain modest ($0.88/share, $63.4M), preserving maximum flexibility for internal growth initiatives.
West's return on invested capital comfortably exceeds its weighted average cost of capital, reflecting substantial structural economic rent creation. As recent major capacity additions at Grand Rapids and Dublin become fully absorbed and capex normalizes toward maintenance levels, capital efficiency and NOPAT generation are poised to inflect higher.
ROIC of ~16.2% to 18.01% exceeds the enterprise WACC of 9.57% by more than 660 to 840 basis points, confirming an entrenched economic moat.
Proprietary Products generated $2,492.1M in revenue with $657.2M in operating profit (26.37% segment margin) in FY2025, while Contract Manufacturing produced $582.0M revenue and $63.4M operating profit (10.89% margin).
| รายได้ | US$3,074,100,000 |
|---|---|
| ต้นทุนรายได้ | US$1,970,100,000 |
| กำไรขั้นต้น | US$1,104,000,000 |
| ค่าใช้จ่ายในการดำเนินงาน | US$519,100,000 |
| กำไรจากการดำเนินงาน | US$584,900,000 |
| รายการที่ไม่ใช่การดำเนินงานและภาษี | -US$91,200,000 |
| กำไรสุทธิ | US$493,700,000 |
| สินทรัพย์รวม | US$4,270,000,000 |
|---|---|
| เงินสด | US$791,300,000 |
| สินทรัพย์หมุนเวียน | US$1,978,200,000 |
| หนี้สินรวม | US$1,094,000,000 |
| หนี้สินหมุนเวียน | US$654,900,000 |
| ส่วนของผู้ถือหุ้น | US$3,176,000,000 |
| กำไรสุทธิ | US$493,700,000 |
|---|---|
| กระแสเงินสดรับจากการดำเนินงาน | US$754,800,000 |
| ค่าเสื่อมราคาและค่าตัดจำหน่าย | US$171,400,000 |
| ค่าตอบแทนที่จ่ายเป็นหุ้น | US$23,800,000 |
| รายการปรับปรุงจากการดำเนินงานอื่น | US$65,900,000 |
| กระแสเงินสดจากการดำเนินงาน | US$754,800,000 |
| เงินสดที่มีอยู่ | US$1,262,300,000 |
| เงินสดต้นงวด | US$484,600,000 |
| ผลกระทบจากอัตราแลกเปลี่ยน | US$22,900,000 |
| เงินสดจ่ายจากการลงทุน | US$285,900,000 |
| Capex | US$285,900,000 |
| เงินสดจ่ายจากการจัดหาเงิน | US$185,100,000 |
| เงินสดปลายงวด | US$791,300,000 |
| กระแสเงินสดจากการลงทุน | -US$285,900,000 |
| กระแสเงินสดจากการจัดหาเงิน | -US$185,100,000 |
แหล่งข้อมูล: SEC EDGAR · ยื่นเมื่อ 2026-02-17 · SEC EDGAR
| รายได้ตามส่วนงานดำเนินงาน | รายได้ | สัดส่วน | เทียบปีก่อน |
|---|---|---|---|
| Proprietary Products | US$2.5B | 81.1% | 6.8% |
| Contract Manufactured Products | US$582M | 18.9% | 4.2% |
แหล่งข้อมูล: SEC EDGAR · ยื่นเมื่อ 2026-02-17 · SEC EDGAR
| รายได้ตามภูมิภาค | รายได้ | สัดส่วน | เทียบปีก่อน |
|---|---|---|---|
| United States | US$1.3B | 43.3% | 8% |
| Other Europe | US$451M | 14.7% | 17% |
| Germany | US$380.3M | 12.4% | 2.1% |
| Other | US$353.3M | 11.5% | 4.2% |
| Ireland | US$333.3M | 10.8% | 3.1% |
| France | US$226.6M | 7.4% | -6.4% |
ข้อมูลการเงิน ณ จุดเวลาที่ใช้ในการวิเคราะห์วันที่ 2026-10-08
| ช่วงเวลา | รายได้ | EBITDA | กำไรสุทธิ | กระแสเงินสดจากการดำเนินงาน | กระแสเงินสดอิสระ | Capex | ค่าเสื่อมราคาและค่าตัดจำหน่าย | ค่าตอบแทนที่จ่ายเป็นหุ้น | การซื้อหุ้นคืน | เงินปันผลที่จ่าย | การออกหนี้สุทธิ | กระแสเงินสดจากการลงทุน | กระแสเงินสดจากการจัดหาเงิน | เงินสดต้นงวด | เงินสดปลายงวด | เงินสดและเงินลงทุน | หนี้สินรวม | อัตรากำไรจากการดำเนินงาน | ROIC | WACC | ส่วนต่าง ROIC−WACC |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2016-12-31 | US$1.5B | US$287.5M | US$143.6M | US$219.4M | US$49.2M | US$170.2M | US$90.7M | US$19.5M | US$52.2M | US$35.8M | — | -US$175.8M | -US$113.9M | — | US$203M | US$203M | US$228.6M | 12.9% | — | 6.3% | — |
| 2017-12-31 | US$1.6B | US$325.6M | US$150.7M | US$263.3M | US$132.5M | US$130.8M | US$96.7M | US$16.1M | US$74.4M | US$39.1M | — | -US$133.6M | -US$109M | US$203M | US$235.9M | US$235.9M | US$197M | 14.1% | — | 6.4% | — |
| 2018-12-31 | US$1.7B | US$353.2M | US$206.9M | US$288.6M | US$183.9M | US$104.7M | US$104.4M | US$15.1M | US$70.8M | US$42.1M | — | -US$100.8M | -US$80.7M | US$235.9M | US$337.4M | US$337.4M | US$196.1M | 14.0% | — | 7.1% | — |
| 2019-12-31 | US$1.8B | US$403.2M | US$241.7M | US$367.2M | US$240.8M | US$126.4M | US$103.4M | US$24.4M | US$83.1M | US$45.1M | — | -US$228M | -US$36.8M | US$337.4M | US$439.1M | US$439.1M | US$257.3M | 16.1% | — | 6.4% | — |
| 2020-12-31 | US$2.1B | US$518.9M | US$346.2M | US$472.5M | US$298.1M | US$174.4M | US$109.1M | US$34M | US$115.5M | US$48.1M | — | -US$179.5M | -US$137.1M | US$439.1M | US$615.5M | US$829.5M | US$255.2M | 19.0% | — | 4.4% | — |
| 2021-12-31 | US$2.8B | US$879.7M | US$661.8M | US$584M | US$330.6M | US$253.4M | US$122.3M | US$37.5M | US$137.1M | US$51.1M | — | -US$253.1M | -US$168.1M | US$615.5M | US$762.6M | US$762.6M | US$253M | 26.6% | — | 5.0% | — |
| 2022-12-31 | US$2.9B | US$808.1M | US$585.9M | US$724M | US$439.4M | US$284.6M | US$120.6M | US$23.7M | US$202.8M | US$54.1M | -US$44.3M | -US$288.2M | -US$293.6M | US$762.6M | US$894.3M | US$894.3M | US$208.9M | 25.4% | — | 7.9% | — |
| 2023-12-31 | US$2.9B | US$844.1M | US$593.4M | US$776.5M | US$414.5M | US$362M | US$137.3M | US$23.3M | US$438.3M | US$57M | -US$2.4M | -US$368.7M | -US$459.6M | US$894.3M | US$853.9M | US$853.9M | US$206.8M | 22.9% | — | 7.7% | — |
| 2024-12-31 | US$2.9B | US$743.8M | US$492.7M | US$653.4M | US$276.4M | US$377M | US$155.4M | US$18.7M | US$560.9M | US$59.1M | -US$27.6M | -US$378.7M | -US$622.6M | US$853.9M | US$484.6M | US$484.6M | US$202.6M | 19.7% | — | 8.3% | — |
| 2025-12-31 | US$3.1B | US$770.6M | US$493.7M | US$754.8M | US$468.9M | US$285.9M | US$171.4M | US$23.8M | US$134M | US$61.2M | -US$1.1M | -US$285.9M | -US$185.1M | US$484.6M | US$791.3M | US$791.3M | US$202.8M | 19.0% | — | 8.9% | — |
West Pharmaceutical Services Inc. (WST) trades at 37.5x forward earnings against a peer median of 14.2x. Its EV/EBITDA of 28.1x compares with a peer median of 14.6x. The comparison uses 4 peers: ResMed Inc., The Cooper Companies Inc., Align Technology Inc. and Intuitive Surgical Inc., as of 2026-10-07 to 2026-10-08.
Capex peaked at $377.0M in FY2024 (12.3% of revenue) after reaching $362.0M in FY2023, before moderating to $285.9M in FY2025 (9.3% of revenue) and $85.9M YTD in H1 2026. In the broader medical supplies industry, capex-to-depreciation sits at 0.8x and capex-to-revenue averages 4.5%.5
In an industry upcycle, rapid clinical adoption of GLP-1 treatments and newly approved biologic entities drives sustained high-teens demand for premium packaging. Customer inventory rebuilding and commercial throughput at Grand Rapids and Dublin accelerate operating leverage, driving consolidated operating margins toward 22.9% by FY2030.
In an industry downcycle or destocking phase, mid-tier biopharma funding constraints reduce clinical trial batch packaging, customer inventory optimizations suppress re-order rates, and contract manufacturing turnover (such as the Q3 2026 CGM contract exit) creates segment revenue troughs, while unrecovered raw material inflation limits gross margin recovery.
West holds an unchallenged leadership position in primary packaging and delivery components for injectable biologics, GLP-1 therapies, and complex pharmaceuticals. With Proprietary Products generating 81.1% of revenue ($2,492.1M in FY2025) and operating margins of 26.37%, West operates at higher profitability than medical technology peers COO (operating margin 20.82%) and ALGN (operating margin 18.25%), though below specialized robotic surgery peer ISRG (33.60%).6
West Pharmaceutical Services trades at an 87.6% premium to intrinsic Fair value ($191.60) and a forward P/E of 37.45x, far above medians for medical technology peers COO (11.46x) and ALGN (11.21x). Implied return is -46.71% against the house Fair value midpoint. Given this extreme valuation disconnect and downside asymmetry, the committee maintains a Sell rating with zero recommended portfolio allocation.2
Risk management is centered on capital preservation given the Sell rating. Investors holding legacy positions face asymmetric downside risk (-46.71% implied return to Fair value of $191.60). Portfolio managers should eliminate long exposure or implement tactical downside hedges, while monitoring quarterly operational checkpoints at the Dublin facility and proprietary product order velocity.
Trading at 37.5x forward earnings and an 87.6% premium to our Fair value of $191.60 per share, the stock offers negative 46.7% implied return and zero margin of safety against unexpected operational or demand headwinds.2
While 10% to 11% organic revenue growth in FY2026 is healthy, the current valuation already discounts aggressive multi-year execution, leaving asymmetric downside risk if GLP-1 packaging growth normalizes toward healthcare supplier peer multiples.3
West possesses wide moat attributes with a 16.2% ROIC and high switching barriers, but paying 87.6% above intrinsic Fair value severely degrades long-term compound returns, making the stock an avoid until a meaningful price correction occurs.1
We recommend a Sell rating on West Pharmaceutical Services. At $359.51, the stock trades at an 87.6% premium to our Fair value of $191.60 per share, presenting an implied return of -46.7%. While West's core packaging franchise and drug master file protections remain structurally intact, the market price demands double-digit volume compounding and multiple sustainability that exceed realistic economic fundamentals.123
Investors should systematically reduce exposure or exit holdings. Reallocating capital to healthcare supply and medical technology peers trading at sector median valuations (such as COO at 11.5x forward P/E or ALGN at 11.2x forward P/E) provides substantially more attractive risk-adjusted return potential.
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
The records this analysis drew on, as they stood when it was run.
Not every cited input appears here: internal calculations and intermediate model outputs have no external record, and some citations could not be matched to one.
Operating income was $584.9M on $3,074.1M revenue in FY2025 (19.03% margin). If Dublin cleanroom qualification stalls and synthetic elastomer/oil costs cannot be fully passed through, operating margin compresses 300 bps below base expectations to under 17.5%, impacting intrinsic fair value by -18%.35
Terminal P/E multiple is modeled at 28.0x, at a large premium to peer median forward P/E of 14.16x and peers COO (11.46x) and ALGN (11.21x). A 20% contraction in the terminal multiple to 22.4x occurs if high-teens HVP expansion decelerates as GLP-1 volumes saturate, impacting intrinsic fair value by -15.5%.
Moderate cost of equity is 9.6348% based on a 5.27% risk-free rate. A 100 bps expansion in the discount rate to 10.63% (aligning toward strict Ke of 10.14%) sharply reduces present values across earnings DCF and multi-stage moat fade models, impacting intrinsic fair value by -12%.1
Rebuts the premium biologics and GLP-1 volume adoption thesis, triggering downward revisions in medium-term revenue CAGR and operating margin normalization.
ปัจจุบัน:16% organic growth in Proprietary Products in Q2 2026
แจ้งเตือนหากProprietary Products organic revenue growth falling below 6.0% YoY over FY2026-FY2027
Indicates protracted capital expenditure overhang without expected operating leverage, depressing free cash flow conversion and returns on invested capital.
ปัจจุบัน:9.30% of revenue in FY2025 ($285.9M on $3,074.1M revenue)
แจ้งเตือนหากCapex-to-revenue ratio remaining above 11.0% over FY2026-FY2027
Prolongs cleanroom under-absorption, deferring $20M in high-margin drug handling sales and diluting consolidated gross margins by 30-50 bps.
ปัจจุบัน:Dublin site in commercial ramping phase with drug handling revenues back-half loaded in FY2026
แจ้งเตือนหากQuarterly drug handling revenue failing to ramp in Q4 2026 or Dublin commercial throughput operating below 50% capacity into 2027
Signals unrecovered raw material and commodity oil inflation or loss of pricing power on proprietary components.
ปัจจุบัน:19.03% in FY2025 ($584.9M operating income on $3,074.1M revenue)
แจ้งเตือนหากOperating margin compressing below 17.50%
| Raw Material and Specialty Elastomer Resin Inflation | low | 6-12 months | Annual contract indexing clauses and premium pricing power on sole-source proprietary components allow West to pass commodity cost increases to pharmaceutical clients with modest time lag.3 |
| Contract Manufacturing Portfolio Transitions and Exits | low | Near term (Q3-Q4 2026) | Contract Manufacturing represents 18.9% of sales ($582.0M in FY2025), and higher-margin drug handling lines ramping at Dublin provide replacement throughput.36 |
Under the moderate discount rate, US$35.77 comes from forecast-period earnings and US$138 from the long-term value, totaling US$174.
Project EPS through the explicit advantage period, fade growth as competition catches up, and discount the full stream at cost of equity.
Apply a terminal P/E to the dated forward EPS path, then discount that future share value back to the analysis date.
Convert the revenue and margin path into after-tax free cash flow, discount the annual per-share amounts and terminal value at WACC, then adjust for signed net debt per current share.
Discounted forecast-period cash flows (US$28.08) plus discounted terminal value (US$96.11) minus signed per current share (-US$8.36) equals the US$133 lens value shown above. Negative net debt is , so subtracting it raises value.
Add depreciation to net income, subtract maintenance capex, divide by diluted shares, and apply a normalized valuation multiple.
Value each distinct segment, subtract corporate overhead and net debt, add probability-weighted optionality, and divide by diluted shares.
Solve for the growth rate that makes the model value equal the report-date share price.
Mix shift toward barrier-coated stoppers and plungers drives premium average selling prices and consolidated gross margin accretion.
Operational validation at Dublin is critical to absorbing fixed overhead and delivering scheduled second-half drug handling revenues.
Normalization of capital intensity unlocks free cash flow conversion as multi-year capacity expansions reach completion.
Given anchor customer revenue concentration, any volume softening or dual-sourcing would directly impact facility utilization and profitability.
| $3.86B |
| $4.14B |
| $4.42B |
| Revenue growth | 9.8% | 6.4% | 7.7% | 7.2% | 6.7% |
| Operating margin | 20.3% | 20.9% | 21.6% | 22.3% | 22.9% |
| Operating income | $683.57M | $749.72M | $836.25M | $923.63M | $1.01B |
| Tax rate | 18.7% | 18.7% | 18.7% | 18.7% | 18.7% |
| NOPAT | $556.09M | $609.90M | $680.29M | $751.37M | $825.11M |
| Reinvestment | $144.58M | $146.38M | $149.66M | $150.27M | $165.02M |
| Reinvestment rate (of NOPAT) | 26.0% | 24.0% | 22.0% | 20.0% | 20.0% |
| Free cash flow to firm | $411.50M | $463.52M | $530.63M | $601.10M | $660.09M |
| Proprietary Products revenue | $2.74B | $2.91B | $3.13B | $3.36B | $3.58B |
| Contract Manufactured Products revenue | $638.78M | $679.52M | $731.58M | $784.21M | $836.95M |
| Terminal growth | 3.0% | 3.0% | 3.0% | 3.0% | 3.0% |
Capex contracted from peak levels of $377.0M in FY2024 to $285.9M in FY2025, while FY2025 FCF expanded to $468.9M.
Reinvestment rate requirements step down from 26.0% in FY2026 to 20.0% by FY2029-FY2030, liberating substantial cash flow for share buybacks and organic returns.
West trades at a forward P/E of 37.45x and a price of $359.51, compared to peer forward P/E ratios of 16.87x for RMD, 11.46x for COO, and 11.21x for ALGN.
Reverse DCF shows the market price implies a 19.41% long-term earnings growth rate, 6.94 percentage points above the analyst base projection of 12.47%, exposing shareholders to severe multiple contraction risk.
| อัตรากำไร |
|---|
| WST | West Pharmaceutical Services Inc. | $25.3B | 37.5x | 7.6x | 28.1x | 19.1% | — |
| RMD | ResMed Inc. | $31.4B | 16.9x | 5.6x | 15.2x | 24.3% | 30.9% |
| COO | The Cooper Companies Inc. | $10.2B | 11.5x | 2.4x | 14.0x | 6.8% | 20.8% |
| ALGN | Align Technology Inc. | $9.9B | 11.2x | 2.4x | 9.8x | 10.2% | 18.2% |
| ISRG | Intuitive Surgical Inc. | $146.4B | 34.3x | 13.3x | 33.8x | 17.4% | 33.6% |
| Decentralized Care and Wearable Self-Injection Devices | positive | Patient self-administration trends drive demand for pre-filled syringes, cartridge systems, and wearable injectors like SmartDose. While early-stage device ramps created near-term margin dilution, the elimination of these drags in H2 2026 contributes 50 bps of full-year margin accretion. |
| Biopharma Supply Chain Redundancy & Dual-Sourcing Pressures | negative | Post-pandemic supply chain audits have prompted select large pharmaceutical innovators to explore secondary sourcing for critical packaging components. While West's top customer represents 15.8% of consolidated sales, regulatory switching hurdles partially mitigate this pressure. |
| Signals prolonged cleanroom qualification delays and extended facility overhead under-absorption; reduce operating margin trajectory by 100 bps. |
| Top Customer Net Sales Concentration | Revenue decline of 15% or more YoY from the primary client | Indicates client dual-sourcing or end-market volume contraction; trigger immediate kill-scenario review and downward revision of terminal multiple. |
| Capex-to-Revenue Ratio | Exceeding 11.0% of revenue in FY2026 or FY2027 | Invalidates capital cycle normalization thesis, increasing reinvestment assumptions and depressing free cash flow projections. |
